"Novel Molecular Super-Glue Platform for Pediatric Cancer Drug Discovery"

St. Jude Children's Research Hospital scientists have developed SJ3149, a potent and selective CK1α degrader, which acts as a "molecular super-glue" by targeting cancer-related proteins for destruction through proteasomal degradation. This compound shows broad anti-cancer activity and may offer a new therapeutic approach for previously undruggable proteins. The research provides a platform for the discovery of novel molecular glues for cancer treatments and offers potential for developing new options for treating different pediatric cancers.